A novel estetrol-containing combined oral contraceptive : European expert panel review
PURPOSE: Despite considerable advances in recently developed combined oral contraceptives (COCs), resulting in lower rates of adverse events while maintaining contraceptive efficacy, there is interest in further innovation.
MATERIALS AND METHODS: Estetrol (E4), a native oestrogen, and progestin drospirenone (DRSP) were combined in a new COC. A European expert panel reviewed the pharmacology, efficacy, and safety and tolerability of this combination. Their findings are presented as a narrative review.
RESULTS: E4 15 mg/DRSP 3 mg in a 24/4 regimen provided effective contraception with good cycle control, characterised by a predictable regular bleeding pattern and minimal unscheduled bleeding, together with a good safety profile. The combination was associated with high user satisfaction, well-being, and minimal changes in body weight. The effects on endocrine and metabolic parameters were limited, and the combination was found to have a limited impact on liver function and lipid and carbohydrate metabolism. Moreover, its effect on several haemostatic parameters was lower than that of comparators containing ethinyl oestradiol (EE) 20 µg/DRSP 3 mg and EE 30 µg/levonorgestrel 150 µg.
CONCLUSION: E4 15 mg/DRSP 3 mg provides safe and effective contraception, with high user satisfaction and predictable bleeding. Further research will evaluate the long-term safety of the COC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception - 27(2022), 5 vom: 01. Okt., Seite 373-383 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gemzell-Danielsson, Kristina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.10.2022 Date Revised 17.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13625187.2022.2093850 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343826275 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343826275 | ||
| 003 | DE-627 | ||
| 005 | 20231226021344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13625187.2022.2093850 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343826275 | ||
| 035 | |a (NLM)35862627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gemzell-Danielsson, Kristina |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A novel estetrol-containing combined oral contraceptive |b European expert panel review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2022 | ||
| 500 | |a Date Revised 17.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Despite considerable advances in recently developed combined oral contraceptives (COCs), resulting in lower rates of adverse events while maintaining contraceptive efficacy, there is interest in further innovation | ||
| 520 | |a MATERIALS AND METHODS: Estetrol (E4), a native oestrogen, and progestin drospirenone (DRSP) were combined in a new COC. A European expert panel reviewed the pharmacology, efficacy, and safety and tolerability of this combination. Their findings are presented as a narrative review | ||
| 520 | |a RESULTS: E4 15 mg/DRSP 3 mg in a 24/4 regimen provided effective contraception with good cycle control, characterised by a predictable regular bleeding pattern and minimal unscheduled bleeding, together with a good safety profile. The combination was associated with high user satisfaction, well-being, and minimal changes in body weight. The effects on endocrine and metabolic parameters were limited, and the combination was found to have a limited impact on liver function and lipid and carbohydrate metabolism. Moreover, its effect on several haemostatic parameters was lower than that of comparators containing ethinyl oestradiol (EE) 20 µg/DRSP 3 mg and EE 30 µg/levonorgestrel 150 µg | ||
| 520 | |a CONCLUSION: E4 15 mg/DRSP 3 mg provides safe and effective contraception, with high user satisfaction and predictable bleeding. Further research will evaluate the long-term safety of the COC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Estetrol | |
| 650 | 4 | |a bleeding pattern | |
| 650 | 4 | |a combined oral contraceptive | |
| 650 | 4 | |a contraceptive efficacy | |
| 650 | 4 | |a drospirenone | |
| 650 | 4 | |a safety profile | |
| 650 | 4 | |a satisfaction | |
| 650 | 7 | |a Contraceptives, Oral, Combined |2 NLM | |
| 650 | 7 | |a Estrogens |2 NLM | |
| 650 | 7 | |a Hemostatics |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Progestins |2 NLM | |
| 650 | 7 | |a Ethinyl Estradiol |2 NLM | |
| 650 | 7 | |a 423D2T571U |2 NLM | |
| 650 | 7 | |a Levonorgestrel |2 NLM | |
| 650 | 7 | |a 5W7SIA7YZW |2 NLM | |
| 650 | 7 | |a Estetrol |2 NLM | |
| 650 | 7 | |a ENB39R14VF |2 NLM | |
| 700 | 1 | |a Cagnacci, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Chabbert-Buffet, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Foidart, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Kubba, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Lete Lasa, Luis Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Mansour, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Neulen, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Neves, Jaoquim |e verfasserin |4 aut | |
| 700 | 1 | |a Palma, Fátima |e verfasserin |4 aut | |
| 700 | 1 | |a Römer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Spaczyński, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Tóth, Vera |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception |d 1998 |g 27(2022), 5 vom: 01. Okt., Seite 373-383 |w (DE-627)NLM096176822 |x 1473-0782 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:5 |g day:01 |g month:10 |g pages:373-383 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13625187.2022.2093850 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 5 |b 01 |c 10 |h 373-383 | ||